Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers

Pathobiology

Volumn 76, Issue 4, 2009, Pages 193-198

  Shimoda, Mitsugi ^a   Sawada, Tokihiko ^a   Kubota, Keiichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Biliary tract cancer; Dihydropyrimidine dehydrogenase; Pancreatic cancer; Thymidylate synthase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

ARTICLE; BILIARY TRACT CANCER; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GALLBLADDER CANCER; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; PANCREAS CANCER; PAPILLARY CARCINOMA; PRIORITY JOURNAL; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; BILE DUCT NEOPLASMS; BILIARY TRACT NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GALLBLADDER NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; THYMIDYLATE SYNTHASE; UP-REGULATION;

EID: 67651089739     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218335     Document Type: Article

References (20)

1. Demographic statistics of the Ministry of Health, Labour and Welfare. http://www. mhlw.go.jp/toukei/saikin/hw/jinkou/kaku-tei03/index.html.
2. Halpern MT, Ward EM, Pavluck AL, Schrag NM, Bian J, Chen AY:Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites:a retrospective analysis. Lancet Oncol 2008;3:189-191.
3. Henson DE, Albores-Saavedra J, Corle D:Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer 1992;70:1498-1501.
4. Seiki Matsuno (Japan Pancreas Society), Pancreatic Cancer Register Committee of Japan Pancreas Society:Summary of 20 years. Suizou 2003;18:97-169.
5. Yamamoto S, Kubota K:Level of 5-fluorode-oxyuridine 5'-monophosphate in cancerous tissue in patients with gastric cancer under preoperative administration of TS-1:a preliminary study. J Exp Clin Cancer Res 2005;24:457-462.
6. Kurebayashi J, Yamamoto Y, Udagawa K, Okubo S, Fukushima M, Sonoo H:Establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydro-pyriminide dehydrogenase in cancer tissues. Oncol Rep 2004;11:973-979.
7. Fukushima M, Fukui Y, Sugimoto Y, Oka T, Nagayama S:Population study of thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltrans-ferase in patients with solid tumors. Proc AACR Meet Abstr 2006;47:854-855.
8. Nagakawa T, Kayahara M, Ohta T, Kitagawa H, Mika mi K, Kurata T, Otsuji S:Dihydropy-rimidine dehydrogenase activity in human pancreatic tumor tissues. Cancer Invest 2000;18:516-520.
9. Kuramochi H, Hayashi K, Uchida K, Mi-yakura S, Shimizu D, Vallbohmer D, Park S, Danenberg KD, Takasaki K, Danenberg PV:5-f luorouraci l-related gene expression levels in primary colorectal cancer and corresponding liver metastasis. Int J Cancer 2006;119:522-526.
10. Heinemann V, Quietzsch D, Gieseler F, Gon-nermann M, Schonekas H, Rost A, Neuhaus H, Haag C , Clemens M, Heinrich B, Vehl ing-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R:Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-3952.
11. Jordan DB, Paul C, James PT, et al:Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma:Eastern cooperative oncology group trial E2297. J Clin Oncol 2002;20:3270-3275.
12. Bramhall SR, Rosemurgy A, Brown PD, et al:Marimastat as first-line therapy for patients with unresectable pancreatic cancer. J Clin Oncol 2001;19:3447-3455.
13. Howard AB, Malcolm JM, John A, et al:Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer. J Clin Oncol 1997;15:2403-2413.
14. Van Cutsem E, van de Velde H, Karasek P, et al:Phase III trial of gemcitabine plus tipi-farnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-1438.
15. Moore MJ, Hamm J, Dancey J, et al:Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adeno-carcinoma of the pancreas:a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2003;21:3296-3302.
16. Okada S, Ueno H, Okusaka T, et al:Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2001;31:7-12.
17. Ishii H, Okusaka T, Funakoshi A:Treatment strategy for unresectable biliary tract cancer-focus on the results of joint multicenter phase II studies of gemcitabine hydrochlo-ride. Jpn Soc Gastroenterol 2005;102:A79.
18. Ichi k aw a W, Ta k a hashi T, Suto K, Yama shit a T, Nihei Z, Shirota Y, Shimizu M, Sasaki Y, Hirayama R:Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 2004;91:1245-1250.
19. Ich i k aw a W, Ue ta ke H, Shi rot a Y, Ya m ad a H , Nishi N, Nihei Z, Sugihara K, Hirayama R:Combination of dihydropyrimidine dehy-drogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimi-dine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003;9:786-791.
20. Kuramochi H, Hayashi K, Uchida K, Naka-jima G, Hatori T, Danenberg KD, Danenberg PV, Yamamoto M:Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Cancer Chemo-ther Pharmacol 2008;63:85-89.